BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11595726)

  • 21. p21WAF1/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells.
    Welcker M; Lukas J; Strauss M; Bartek J
    Cancer Res; 1998 Nov; 58(22):5053-6. PubMed ID: 9823309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
    Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
    Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.
    Scaini MC; Rossi E; de Siqueira Torres PL; Zullato D; Callegaro M; Casella C; Quaggio M; Agata S; Malacrida S; Chiarion-Sileni V; Vecchiato A; Alaibac M; Montagna M; Mann GJ; Menin C; D'Andrea E
    Mutat Res; 2009 Dec; 671(1-2):26-32. PubMed ID: 19712690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo.
    Lee SH; Kim MS; Kwon HC; Park IC; Park MJ; Lee CT; Kim YW; Kim CM; Hong SI
    Int J Mol Med; 2000 Nov; 6(5):559-63. PubMed ID: 11029524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
    Yarbrough WG; Buckmire RA; Bessho M; Liu ET
    J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The p16(INK4A) protein and flavopiridol restore yeast cell growth inhibited by Cdk4.
    Moorthamer M; Panchal M; Greenhalf W; Chaudhuri B
    Biochem Biophys Res Commun; 1998 Sep; 250(3):791-7. PubMed ID: 9784425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.
    Ruas M; Brookes S; McDonald NQ; Peters G
    Oncogene; 1999 Sep; 18(39):5423-34. PubMed ID: 10498896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
    Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
    Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
    Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
    Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cyclin-dependent kinase inhibitory proteins in normal and transformed choroidal melanocytes].
    Mouriaux F; Maurage CA; Labalette P; Casagrande F; Malecaze F; Darbon JM
    J Fr Ophtalmol; 1999 Apr; 22(3):339-46. PubMed ID: 10337591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.
    Suzuki A; Hayashida M; Ito T; Kawano H; Nakano T; Miura M; Akahane K; Shiraki K
    Oncogene; 2000 Jul; 19(29):3225-34. PubMed ID: 10918579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.
    Al-Khalaf HH; Hendrayani SF; Aboussekhra A
    Mol Cancer Res; 2011 Mar; 9(3):311-9. PubMed ID: 21270107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
    Sandhu C; Peehl DM; Slingerland J
    Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genes involved in melanoma: an overview of INK4a and other loci.
    Castellano M; Parmiani G
    Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells.
    Fahham N; Sardari S; Ostad SN; Vaziri B; Ghahremani MH
    J Cell Biochem; 2010 Dec; 111(6):1598-606. PubMed ID: 21053367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia.
    Said TK; Moraes RC; Singh U; Kittrell FS; Medina D
    Cell Growth Differ; 2001 Jun; 12(6):285-95. PubMed ID: 11432803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E2F-dependent repression of topoisomerase II regulates heterochromatin formation and apoptosis in cells with melanoma-prone mutation.
    Jiao W; Lin HM; Timmons J; Nagaich AK; Ng SW; Misteli T; Rane SG
    Cancer Res; 2005 May; 65(10):4067-77. PubMed ID: 15899796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.